Effect of a fermented blueberry-alfalfa drink on tolerability and blood parameters of healthy volunteers

Impact of a fermented blueberry-alfalfa drink on safety and tolerability and on blood parameters of healthy volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78436478

Enrollment

Registered

2022-09-30

Start date

2021-09-27

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of fermented blueberry-alfalfa drink on tolerability and blood parameters of healthy volunteers Not Applicable

Interventions

All participants drink the 30 ml fermented blueberry-alfalfa drink daily for 21 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Aged 18 years and over 3. Willingness to maintain a stable diet and physical activity level 4. Willingness to cease using probiotic products and supplements (except vitamin D) during the study period 5. Normal or not clinically relevant deviations in safety laboratory values

Exclusion criteria

Exclusion criteria: 1. Acute or chronic inflammatory disease 2. Gastrointestinal diseases (e.g. Crohn's disease, inflammatory bowel disease, ulcerative colitis)

Design outcomes

Primary

Measure	Time frame
Adverse events measured using a patient diary (follow chart), a self-administered follow-up questionnaire filled out once per day for 21 days	—

Secondary

Measure	Time frame
1. Safety parameters (e.g. white blood [WBC] and red blood [RBC] indices, inflammation [CRP], kidney and liver parameters) measured by standard laboratory methods in the United Laboratories of the Tartu University Hospital at baseline and the end of the study 2. Experimental parameters (e.g. adiponectin and leptin) measured from the blood samples using ELISA commercial kits (R&D Systems) and blood samples taken at baseline and the end of the study	—

Measure

Time frame

1. Safety parameters (e.g. white blood [WBC] and red blood [RBC] indices, inflammation [CRP], kidney and liver parameters) measured by standard laboratory methods in the United Laboratories of the Tartu University Hospital at baseline and the end of the study 2. Experimental parameters (e.g. adiponectin and leptin) measured from the blood samples using ELISA commercial kits (R&D Systems) and blood samples taken at baseline and the end of the study

—

Countries

Estonia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026